Palbociclib and Cetuximab in Metastatic Colorectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 23, 2018

Primary Completion Date

May 29, 2023

Study Completion Date

January 26, 2026

Conditions
Cancer of the ColonColon CancerColon NeoplasmsColonic CancerNeoplasms, Colonic
Interventions
DRUG

Cetuximab

Loading dose on day 1 of week 1 of 400 mg/m2 via IV over 2 hours Subsequent doses of 250 mg/m2 via IV over 1 hour weekly for 4 weeks (28 days) in combination with palbociclib

DRUG

Palbociclib

125 mg taken orally once daily on days 1-21, then 7 days off

Trial Locations (1)

27599-7295

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT03446157 - Palbociclib and Cetuximab in Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter